Summary & Overview
CPT 81320: PLCG2 Gene Variant Detection, Molecular Diagnostic Test
CPT code 81320 identifies a molecular diagnostic laboratory test performed to detect common variants in the PLCG2 gene. This genetic assay is used in clinical diagnostic workflows where identification of PLCG2 changes informs disease characterization, research, or targeted clinical management. Nationally, genetic and molecular testing codes like CPT code 81320 are important for precision medicine, lab service billing, and payer coverage policies as demand for targeted genetic testing grows.
Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Coverage and reimbursement policies for molecular diagnostics vary across payers and affect access to testing in clinical pathways.
Readers will learn the clinical context of CPT code 81320, typical sites of service, and which major payers are considered in national comparisons. The publication provides benchmarks and policy-relevant context for laboratory billing, outlines common payer coverage patterns, and summarizes clinical implications of PLCG2 testing. Data not available in the input is noted where necessary.
Billing Code Overview
CPT code 81320 describes a laboratory test in which a lab analyst performs the technical procedure to detect common changes in the phospholipase C gamma 2 gene (PLCG2). This is a molecular diagnostic assay focused on identifying genetic variants in the PLCG2 gene that may be relevant to clinical evaluation.
Service type: Molecular diagnostic / genetic testing
Typical site of service: Clinical diagnostic laboratory or pathology laboratory (technical component performed by lab personnel)
Clinical & Coding Specifications
Clinical Context
A patient with suspected immune dysregulation or an inherited/autoinflammatory syndrome is referred by an immunologist or geneticist for targeted genetic testing of the phospholipase C gamma 2 gene (PLCG2). Typical patients include adults or children with recurrent infections, atypical antibody responses, cold-induced urticaria, inflammatory symptoms, or a family history suggestive of PLCG2-associated disorders. The clinical workflow begins with the ordering clinician documenting the indication and obtaining informed consent for molecular testing. A blood sample (EDTA) or extracted DNA is collected in an outpatient clinic or hospital laboratory and sent to a molecular diagnostics laboratory. The laboratory performs the technical assay to detect common PLCG2 sequence changes, including targeted variant analysis or a focused gene panel. Results are reviewed by a laboratory director and reported to the ordering clinician, who integrates findings with clinical data and may refer the patient for genetic counseling or additional testing if a pathogenic or likely pathogenic variant is detected.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 | Professional component | Use when reporting only the professional interpretation and report of the molecular test separate from the technical processing. |
TC |